European Journal of Clinical Pharmacology

, Volume 47, Issue 3, pp 267–274 | Cite as

Haemodynamic dose-efficacy of levosimendan in healthy volunteers

  • J. Lilleberg
  • M. S. Nieminen
  • S. Sundberg
  • M. Häyhä
  • J. Akkila
Pharmacodynamics

Abstract

Levosimendan is a new calcium-sensitiser intended for the treatment of congestive heart failure. The results of preclinical studies indicate it has positive inotropic and vasodilator effects. In the open study reported here up to 5 mg levosimendan and vehicle were administered to 8 healthy male volunteers at one- to 2-week intervals. Efficacy was evaluated using M-mode echocardiography, and by measuring systolic time intervals, recording ECG and measuring blood pressure.

For almost all haemodynamic parameters except heart rate (HR) the maximum effect was seen 10 or 20 min after drug infusion. Effects 10 min after infusion of drug and vehicle were compared.

HR was significantly increased 10 min only after infusion of 5 mg: significant increases were seen 60 min after infusions of 2, 3 and 5 mg (4, 8 and 17 beats min−1, respectively).

Diastolic blood pressure was significantly lower after doses of 1 mg or more. The decrease after 5 mg was 17 mm Hg. Systolic blood pressure tended to increase. Fractional shortening (FS) and ejection fraction (EF) increased significantly after doses of 1 mg and higher. EF 10 min after infusion of vehicle was 54%. It increased to 73% after 5 mg. Decreases in electromechanical systole (QS2i) 10 min after 2, 3 and 5 mg were significant. There were no clinically significant adverse events or changes in laboratory safety values.

The changes in QS2i, FS, EF and blood pressure indicate that levosimendan has positive inotropic and vasodilator effects in healthy subjects.

Key words

Levosimendan Calcium sensitiser echocardiography systolic time intervals healthy volunteers adverse events 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kass RS, Lederer WJ, Tsien RW, Weingart R (1978) Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibres. J Physiol 291: 187–208Google Scholar
  2. 2.
    Hasenfuss G, Holubarsch C, Just H, Blanchard E, Mulieri LA, Alpert NR (1987) Energetic aspects of iontropic interventions in rat myocardium. Basic Res Cardiol 82: 251–259PubMedGoogle Scholar
  3. 3.
    Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G (1991) The novel cardiotonic agent EMD 53998 is a potent calcium sensitizer. J Cardiovasc Pharmacol 18: 17–27PubMedCrossRefGoogle Scholar
  4. 4.
    Ovaska M, Haikala H, Lundström K, Korkolainen T, Taskinen J, Lindén I-B (1992) Studies on calcium-dependent binding of simendan to troponin complex and troponin C. J Mol Cell Cardiol 24 [Suppl I]: S260Google Scholar
  5. 5.
    Haikala H, Lindén I-B, Pohto P (1992) Simendan, a novel calcium sensitizer, is as potent and efficient in the skinned fibre as in the electrically paced papillary muscle J Mol Cell Cardiol 24 [Suppl I]: S260Google Scholar
  6. 6.
    Haikala H, Lindén I-B, Pohto P (1992) Changes in contractionrelaxation cycle by levosimendan indicate calcium sensitization in paced papillary muscle without impairment of relaxation (abstract) Eur Heart J 13 [Supol]: P765Google Scholar
  7. 7.
    Edes I, Papp J, Csanady M (1992) A unique effect of the new positive drug simendan (OR-1259) on the phosphorylation of key intracellular proteins (abstract). Eur Heart J 13 [Suppl]: 167Google Scholar
  8. 8.
    Edes I, Csanady M, Papp J (1993) The effects of new calcium sensitizers (levosimendan, pimobendan and EMD 53 998) on myocardial protein phosphorylation (abstract) Eur Heart J 14 [Suppl]: 198Google Scholar
  9. 9.
    Edes I, Papp J, Csanady M (1991) The effects of a new calcium sensitizer simendan, on intracellular protein phosphorylation (abstract). J Mol Cell Cardiol 24 [Suppl V]: S93Google Scholar
  10. 10.
    Raasmaja A, Talo A, Nissinen E, Lindén I-B, Pohto P (1991) Biochemical mechanisms of the novel cardiotonic agent OR-1259. J Mol Cell Cardiol 23 [Suppl V]: S129CrossRefGoogle Scholar
  11. 11.
    Vegh A, Udvary E, Papp J (1992) Effects of simendan in a model of acute heart failure produced by severe regional ischaemia in dogs. J Mol Cell Cardiol 24 [Suppl V]: S45CrossRefGoogle Scholar
  12. 12.
    Lilleberg J, Leikola-Pelho T, Sundberg S, Nieminen MS (1994) Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers. Cardiovasc Drugs Ther 8: 263–269PubMedCrossRefGoogle Scholar
  13. 13.
    Bazett HC (1920) An analysis of the time-relations of electrocardiogram. Heart 7: 353–370Google Scholar
  14. 14.
    Upton MT, Gibson DG (1978) The study of left ventricular function from digitized echocardiograms. Prog Cardiovasc Dis 20: 359–384PubMedCrossRefGoogle Scholar
  15. 15.
    Roelandt J, Gibson DG (1980) Recommendations for standardization of measurements from digitized echocardiograms. Eur Heart J 1: 375–378PubMedGoogle Scholar
  16. 16.
    Teichholz LE, Kreulen T, Herman MV, Gorlin R (1976) Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37: 7–11PubMedCrossRefGoogle Scholar
  17. 17.
    Li Q, Belz GG (1993) Systolic time intervals in clinical pharmacology Eur J Clin Pharmacol 44: 415–421PubMedCrossRefGoogle Scholar
  18. 18.
    Weissler AM, Harris WS, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37: 149–159PubMedGoogle Scholar
  19. 19.
    Spodick DH, Doi YL, Bishop RL, Hashimoto T (1984) Systolic time intervals reconsidered. Reevaluation of the preejection period: absence of relation to heart rate. Am J Cardiol 53: 1667–1670PubMedCrossRefGoogle Scholar
  20. 20.
    Sundberg S (1986) Influence of heart rate on systolic time intervals. Am J Cardiol 58: 1144–1145PubMedCrossRefGoogle Scholar
  21. 21.
    Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet I: 307–310Google Scholar
  22. 22.
    Kupari M (1984) Reproducibility of M-mode echocardiographic assessment of left ventricular function. Significance of the temporal range of measurements. Eur Heart J 5: 412–418PubMedGoogle Scholar
  23. 23.
    Groundstroem K, Huikuri H, Korhonen U, Ikäheimo M, Heikkila J, Takkunen J (1987) Comparison of echocardiographic and radionuclide methods with contrast angiography assessment of left ventricular function — response to isometric exercise in subjects without definite heart disease. Ann Clin Res 10: 187–193Google Scholar
  24. 24.
    DeMaria AN, Neumann A, Schubart PJ, Lee G, Mason DT (1979) Systematic correlation of cardiac chamber size and ventricular performance determined with echocardiography and alterations in heart rate in normal persons. Am J Cardiol 43: 1–9PubMedCrossRefGoogle Scholar
  25. 25.
    Quinones AM, Gaasch WH, Cole JS, Alexander JK (1975) Echocardiographic determination of left ventricular stress-velocity relations in man with reference to the effects of loading and contractility. Circulation 51: 689–700PubMedGoogle Scholar
  26. 26.
    Quinones MA, Gaasch WH, Alexander JK (1976) Influence of acute changes in preload, afterload, contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man. Circulation 53: 293–302PubMedGoogle Scholar
  27. 27.
    Gibson DG (1978) Use of the systolic time intervals in clinical pharmacology. Br J Clin Pharmacol 6: 97–102PubMedGoogle Scholar
  28. 28.
    Belz GG, Stern HC, Butzer R (1985) Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers. J Cardiovasc Pharmacol 7: 86–90PubMedCrossRefGoogle Scholar
  29. 29.
    Stern HC, Matthews JH, Belz GG (1984) Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects. Br Heart J 52: 435–439PubMedGoogle Scholar
  30. 30.
    Plotnick GD (1989) Changes in diastolic function — difficult to measure, harder to interpret. Am Heart J 118: 637–641PubMedCrossRefGoogle Scholar
  31. 31.
    Bahler RC, Vrobel TR, Martin P (1983) The relation of heart rate and shortening fraction to echocardiographic indexes of left ventricular relaxation in normal subjects. J Am Coll Cardiol 2: 926–933PubMedCrossRefGoogle Scholar
  32. 32.
    Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70: 797–801PubMedCrossRefGoogle Scholar
  33. 33.
    Morganroth J, Brozovich FV, McDonald JT, Jacobs RA (1991) Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67: 774–776PubMedCrossRefGoogle Scholar
  34. 34.
    Viitasalo MT, Kala R, Eisalo A (1982) Ambulatory electrocardiographic recording in endurance athletes. Br Heart J 47: 213–220PubMedGoogle Scholar
  35. 35.
    Lues I, Beier N, Jonas R, Klockow M, Haeusler G (1993) The two mechanisms of action of racemic cardiotonic EMD 53 998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 21: 883–892PubMedCrossRefGoogle Scholar
  36. 36.
    Endoh M, Shibasaki T, Satoh H, Norota I, Ishihata A (1991) Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium. J Cardiovasc Pharmacol 17: 365–375PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • J. Lilleberg
    • 1
  • M. S. Nieminen
    • 1
  • S. Sundberg
    • 2
  • M. Häyhä
    • 2
  • J. Akkila
    • 2
  1. 1.Cardiovascular Laboratory, First Department of MedicineHelsinki University Central HospitalHelsinkiFinland
  2. 2.Orion-Farmos PharmaceuticalsEspooFinland

Personalised recommendations